| Name | thrombin |
|---|---|
| Synonyms | Coagulation factor II; Coagulation factor II variant; F2; F2 protein; F2 protein precursor; Factor II; PT; Prothrombin… |
| Name | diatomaceous earth |
|---|---|
| CAS | diatomite |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 7574046 | Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA: Influence of high-dose aprotinin on anticoagulation, requirement, and celite- and kaolin-activated clotting time in -pretreated patients undergoing open-heart surgery. Anesthesiology. 1995 Oct;83(4):679-89; discussion 29A-30A. Parameters of coagulation that are indicators of thrombin generation and activity (F1+2 prothrombin fragments, thrombin-antithrombin III complex, and fibrin monomers), parameters of fibrinolysis (D-dimers), aprotinin, and plasma concentrations were measured. |
2(0,0,0,2) | Details |
| 16631662 | Nielsen VG: Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg. 2006 May;81(5):1720-7. |
2(0,0,0,2) | Details |
| 7515704 | Huyzen RJ, Harder MP, Huet RC, Boonstra PW, Brenken U, van Oeveren W: Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients. J Cardiothorac Vasc Anesth. 1994 Apr;8(2):153-6. Three different clotting times, the celite-based ACT, the kaolin-based activated coagulation time (AKT) and the high-dose thrombin time (HITT), were compared in a prospective, double-blind, placebo-controlled study of 20 patients who were to undergo cardiopulmonary bypass. |
2(0,0,0,2) | Details |
| 16632802 | Carroll RC, Chavez JJ, Simmons JW, Snider CC, Wortham DC, Bresee SJ, Cohen E: Measurement of patients' bivalirudin plasma levels by a thrombelastograph ecarin clotting time assay: a comparison to a standard activated clotting time. Anesth Analg. 2006 May;102(5):1316-9. This was compared to a standard Hemochron ACT assay using diatomaceous earth. With the TEG assay, the direct thrombin activator, ecarin, was used to initiate coagulation and measured as the reaction time. |
1(0,0,0,1) | Details |
| 9296400 | Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E: Antithrombin III during cardiac surgery: effect on response of activated clotting time to and relationship to markers of hemostatic activation. Anesth Analg. 1997 Sep;85(3):498-506. Because AT is variably, and sometimes extensively, reduced in many patients before and during CPB, AT supplementation in these patients might be useful in reducing excessive thrombin-mediated consumption of labile hemostatic blood components, excessive microvascular bleeding, and transfusion of blood products. |
1(0,0,0,1) | Details |
| 17000790 | Audu P, Nielsen VG, Armstead V, Powell G, Kim J, Kim L, Mehta M: The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography. Anesth Analg. 2006 Oct;103(4):841-5. The TFPI/FXa complex then subsequently binds with TF/activated factor VII (FVIIa) complex, ultimately inhibiting thrombin generation. |
1(0,0,0,1) | Details |
| 126430 | Soulier JP, Prou-Wartelle O: [Effects of various adsorbants on coagulation factors (author's transl)] . Nouv Rev Fr Hematol. 1975 Mar-Apr;15(2):195-211. The main properties of each adsorbant are listed as well as several applications such as: selective adsorption of fibrinogen, separation between fibrinogen and factor VIII, separation of from the other components of the prothrombin complex. |
1(0,0,0,1) | Details |